Alterity Therapeutics (PRNAD) Receivables (2009 - 2025)

Alterity Therapeutics (PRNAD) has reported Receivables for 16 consecutive years, with $4.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Receivables rose 20.86% year-over-year to $4.5 million; the TTM figure through Dec 2025 stood at $4.5 million (up 20.86% YoY), while the FY2025 annual figure was $2.5 million, down 5.32% from the prior year.
• Receivables came in at $4.5 million for Q4 2025 at Alterity Therapeutics, up from $2.5 million in the prior quarter.
• The five-year high for Receivables was $4.6 million in Q4 2022, with the low at $86657.0 in Q2 2023.
• Average Receivables over 5 years is $3.3 million, with a median of $3.6 million recorded in 2022.
• Across the five-year window, Receivables soared 8095.97% in 2021 and tumbled 97.44% in 2023, its largest moves.
• Year by year, Receivables stood at $4.6 million in 2021, then increased by 1.95% to $4.6 million in 2022, then decreased by 16.22% to $3.9 million in 2023, then dropped by 4.58% to $3.7 million in 2024, then grew by 20.86% to $4.5 million in 2025.
• According to Business Quant data, Receivables over the past three periods registered $4.5 million, $2.5 million, and $3.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.